Moreover, the lipid nanoparticle (LNP)-mediated WT FBP1 mRNA delivery designed by this group can effectively inhibit tumor growth, finding a potential therapy for ccRCC and HCC. The gene discussed is FBP1; the disease is nonpapillary renal cell carcinoma.